News Italian decision sets up launch of Oncopeptides' Pepaxti Oncopeptides hopes to reignite growth in multiple myeloma drug Pepaxti after getting reimbursement approval in Italy.
News Santhera preps UK Duchenne drug launch after NICE says yes Santhera will launch its new drug for Duchenne muscular dystrophy in the UK within the next few weeks after getting the green light for NHS coverage.
News AIs can be used for fracture detection, says NICE NICE has said that four artificial intelligence technologies can be deployed by the NHS to detect fractures on X-rays in urgent care.
News New drugs 'benefit patients, but maybe not populations' The money spent by the NHS on newly approved therapies recommended by NICE might have been better spent elsewhere, according to a new study.
News Price deal opens door to NHS use of Santhera DMD drug Santhera's Duchenne muscular dystrophy (DMD) therapy Agamree has been cleared for NHS use after a confidential pricing agreement.
News Mounjaro cleared for NHS use, but patients may have to wait Many patients can expect a long wait for access to Eli Lilly's obesity shot Mounjaro, even though it has been recommended for routine NHS use by NICE
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
